Chapter 42: Biotechnology & Industrial Microbiology Applications

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome to the Deep Dive.

Today, we're tackling a pretty hefty stack of sources on industrial microbiology and biotechnology.

We're aiming to distill it all down for you, give you the must -know insights.

We're basically looking at how we went from

accidentally finding useful stuff in molds to actively engineering tiny microbial factories, factories that make almost everything, drugs, fuel, even high -tech materials.

Our goal here is really to shortcut your learning curve on this whole complex field, but I think to really grasp the opportunities, we kind of have to start with a, well, a massive problem, a dilemma, really.

You mean the antibiotic crisis.

Exactly.

That's it.

Yeah.

And it's not just a medical issue, is it?

It's like a fundamental market failure.

We hear it costs billions, takes over a decade to bring any drug to market.

Precisely.

And think about it, if you develop a statin, say, that's a drug someone might take for life,

decades of profit, potentially.

Now, compare that to a brand new antibiotic.

You actually hope it's used sparingly, right?

Because the minute it's widely used, resistance starts building up.

So it's never going to be a blockbuster drug, not in the same way.

Never.

The huge upfront costs versus that really short, limited profit window, it just creates this economic disincentive.

It actively works against what we desperately need from a public health perspective.

And the clock's really ticking because historically, discovery just hit a wall.

It really did.

I mean, think about it.

Seven major antibiotic classes discovered between roughly 1935 and 1962.

Great progress.

Then,

basically nothing new for almost 40 years.

Zero new classes introduced until around 2000.

We were just tweaking the old drugs while resistance kept climbing.

So now we're forced into these really innovative, sometimes expensive strategies.

We're mining genes from stuff we can't even grow in the lab, looking in deep sea trenches inside insects.

Because we've barely scratched the surface of microbial diversity.

Exactly.

We still haven't cultured maybe 99 % of all bacteria and archaea out there.

The potential is huge, but hard to access.

Okay, so we need these microbial, natural products, and we need new ways to find them or make them.

Let's unpack the mechanisms these tiny factories actually use.

We rely heavily on microbes for this, don't we?

Over 65 % of known antibiotics come from just streptomyces bacteria and various filamentous fungi.

They're the work horses.

And the industrial process to get these products is incredibly precise.

Take penicillin, for example.

To get the absolute maximum yield,

manufacturers figured out you actually have to stress the microbe.

Stress it?

Why does that work?

Wouldn't you just feed it loads of nutrients?

But see, penicillin is what we call a secondary metabolite.

It's not made during the microbes main growth spurt.

It's produced after that, often when nutrients are getting scarce, when the cell is well -stressed.

So to induce that state, they carefully control the food.

They use a sugar, lactose that's broken down slowly.

Right, kind of drip feeding it.

Exactly.

And they limit the nitrogen supply.

This basically forces the fungus, penicillium chrysogenum, to switch gears, stop focusing on growing, and start pumping out penicillin.

It's like custom manufacturing at cellular level.

That's clever.

And if they want a specific type of penicillin, like penicillin G.

Simple.

Well, relatively simple.

They just add a specific precursor chemical, like phenylacetic acid, to the mix, and the fungus incorporates it right into the final molecule.

Tailor made.

Okay, moving from drugs to, say, the food industry.

We use microbes there too, right, for things like amino acids?

Absolutely.

Things like lysine for supplements or glutamate MSG for flavor enhancement.

These are primary metabolites made during active growth.

Okay, so different strategy needed there.

Right.

For these, we often use highly engineered bacteria like chorinobacterium glutamicum.

And what's really fascinating here is how we engineer them.

How so?

We actually intentionally impair the bacteria's metabolism.

You break them on purpose.

Sort of.

We engineer a specific bottleneck.

We limit their ability to process a key intermediate molecule, alpha -ketoglutarate, in the case of glutamate production.

Like a metabolic roadblock.

Exactly like that.

By blocking that path, the metabolic building blocks have nowhere else to go, so they get shunted towards making massive amounts of the amino acid we want.

Glutamate floods out.

And they secrete it.

Yeah, we also make sure their cell membranes are a bit leaky so the product doesn't just build up inside.

It gets released into the broth for easy collection.

Okay, this idea of using microbial parts leads us nicely into biocatalysis.

What exactly is that, and why is it often better than traditional chemistry?

So biocatalysis is basically using microbial enzymes, you know, the cell's little molecular machines like transferases or oxygenases, as industrial catalysts to make very specific chemical changes.

And the advantages.

Oh, they're huge.

It's generally much cleaner than traditional chemical synthesis.

Cleaner how?

Less waste.

Less waste, yes, but also more specific.

One massive advantage is stereospecificity.

Right, the mirror image molecule problem.

Exactly.

Chemical reactions often produce a mix of two mirror image forms, isomers.

But often only one form is biologically active.

The other might be useless, or worse, actually harmful.

Like a thalidomide tragedy.

Precisely.

Microbial enzymes, though, are naturally stereospecific.

They produce only the desired active isomer.

Like the fungus Rhizopus nigricans hydroxylating progesterone, does it with absolute precision, only adding the hydroxyl group at the exact right spot.

Surgical precision at the molecular level.

And you mentioned other advantages.

Yes.

These enzyme reactions usually happen under really mild conditions.

Normal temperatures, neutral pH.

Not the extreme heat or harsh chemicals you sometimes need in traditional synthesis.

Right.

Which means less energy consumption, less hazardous waste, safer processes.

It's just elegant.

Very elegant.

Okay, shifting gears slightly.

From custom chemistry to public challenges.

Let's talk vaccines.

What happens when you can't easily grow the pathogen?

Or its surface molecules look too much like our own cells.

Like that Neisseria meningititis cerevar B you mentioned.

Yeah.

MemB was a tough nut to crack with traditional methods for exactly those reasons.

This is where a really powerful engineering approach comes in.

Reverse vaccinology.

Reverse the vaccinology.

Okay, what's that?

Instead of starting with the actual bacterium or virus and trying to figure out what parts trigger immunity.

Yeah.

You start with its complete genome sequence, its DNA blueprint.

So you mine the genome first, looking for potential targets before you even touch the microbe.

Exactly.

You use bioinformatics to scan the entire genome and predict all the potential proteins, especially those likely to be on the surface or secreted.

Like creating a suspect list.

A very targeted suspect list.

You then filter that list based on strict criteria.

Is it actually produced during infection?

Is it accessible to the immune system?

Is it essential for the pathogen survival?

And crucially, can it provoke a protective immune response?

And this worked for MemB.

It did.

This rational genome first approach directly led to the development and approval of the MemB vaccine in 2014.

It solved a problem that decades of conventional vaccine research couldn't.

That's a fantastic example of engineering meeting biology.

And it bridges nicely into our next topic, applying this kind of thinking to large scale production, like biofuels.

Section 42 .2 dives into that.

Right.

Biofuels.

It's a really dynamic field.

You know, the US has this goal, substituting 30 % of gasoline with biofuels by 2030.

Which currently means corn ethanol, mostly.

Mostly corn ethanol, yeah.

But that's causing unintended consequences, isn't it?

Like driving up food prices, requiring more pesticides.

And the ethanol itself has physical drawbacks for our current systems.

It really does.

First, it just doesn't pack the same energy punch as gasoline.

Lower energy density.

Right.

And critically, it sucks up water.

It's hygroscopic.

Thinking.

Meaning it absorbs moisture from the air or from anywhere, really.

Our existing pipelines always have some moisture, so you can't just pump ethanol through them.

It would get contaminated and potentially cause corrosion.

So you have to dehydrate it expensively.

Exactly.

Costly extra steps like double distillation are needed.

Okay, so ethanol is not ideal.

That's pushed research towards other sources,

like cellulosic biofuels, using like corn stalks and wood chips.

Yeah, using agricultural residues or dedicated energy crops.

The raw material, the cellulose, is abundant and doesn't compete directly with food.

But getting the sugars out of that tough cellulose is hard.

Very hard.

Traditionally, it requires harsh chemicals, high heat, lots of energy, but here

biocatalysis offers a solution.

Using microbes or their enzymes again?

Precisely.

Engineering microbes or finding naturally heat -tolerant ones that produce enzymes capable of breaking down cellulose efficiently under milder conditions.

It makes the whole process potentially much cheaper and greener.

What about other biofuels?

I remember reading about hydrogen, H2.

Ah, yes.

Hydrogen.

The ultimate clean fuel, potentially.

Burns to produce just water.

And energy -wise, it's fantastic about three times the energy per unit weight compared to gasoline.

And microbes can make H2?

They can, several ways.

Through fermentation, like some bacteria do, or using photosynthesis.

Some photosynthetic microbes, oxygenic ones like algae, can produce H2, but often only at night.

And the process gets shut down by the very H2 it produces.

How very efficient, then.

Not ideal.

But there's a lot of interest in the enzymes involved.

Microbes use enzymes called hydrogenase, or nitrogenase, to make H2.

What's the difference?

Well, hydrogenase is simpler, but as I mentioned, it often suffers from product inhibition.

The H2 it makes shuts it down.

You'd have to constantly remove the H2, which adds complexity.

Right.

Nitrogenase, on the other hand, is the enzyme complex microbes normally use to fix atmospheric nitrogen gas, N2, into ammonia.

It's complicated and needs a lot of energy ATP.

So why is it interesting for H2 production?

Because if you remove the nitrogen gas, N2, from its environment, the nitrogenase enzyme, lacking its usual substrate, starts producing only hydrogen gas, H2, as a byproduct of its reaction cycle.

And here's the key.

It is not inhibited by the H2 it produces.

Ah, so it can just keep churning out H2.

Potentially, yes.

It can reach almost 100 % efficiency in converting energy to H2 under those conditions.

The big challenge remains its huge ATP requirement.

So researchers are actively engineering ways around that, trying to make it more energy efficient.

Okay, so we've got the microbes.

We've got potential products from antibiotics to fuels.

But making something in a lab slask is one thing.

Scaling it up is another beast entirely.

Section 42 .3 tackles this.

Oh, absolutely.

The scale -up challenge is immense.

And first, maybe we should clarify a term,

fermentation.

Right, because it means different things, doesn't it?

It does.

In basic physiology, fermentation is a specific metabolic process, pyruvate reduction, without oxygen.

But in industry… It just means growing lots of cells.

Exactly.

Any mass culture of cells, microbial, plant, animal, usually in these enormous vessels called fermenters or bioreactors, we're talking tanks that can hold 100 ,000 liters, sometimes much more.

And the challenge is keeping things consistent between that tiny lab flask, maybe 250 milliliters, and that massive 100 ,000 -liter tank.

That seems almost impossible.

It's incredibly difficult.

Think about maintaining the exact same temperature, pH, oxygen levels, nutrient concentrations,

everywhere inside that huge volume.

How do they even do it?

Those tanks look like giant steel silos.

They're packed with technology.

If you could look inside an industrial stirred fermenter, you'd see massive impellers, like boat propellers, constantly mixing.

There are systems to bubble in sterile air spargers, cooling jackets on the outside to remove the massive amount of heat generated by all those actively growing cells.

And sensors everywhere, I assume?

Constantly.

Probes monitoring, dissolved oxygen, pH, temperature, pressure, foam levels, all feeding data back to computers that control the inputs in real -time adjusting aeration, adding acid or base, controlling temperature precisely.

It's a highly engineered environment.

You mentioned controlling inputs.

One key technique is continuous feed, right?

Adding the food gradually.

Why is that so important?

It comes down to efficiency and avoiding waste.

If you just dump a massive load of glucose, the cell's favorite food in all at once.

They might go into overdrive, breaking it down too quickly, maybe incompletely.

This is called excess catabolism.

They might produce waste products instead of channeling that energy and carbon towards the product you actually want.

So slow and steady wins the race.

In this case, yes.

Gradual, continuous feeding keeps the metabolic pathways balanced, ensuring the substrate goes towards making your target compound, maximizing the yield.

Okay.

And that ties back to something you mentioned earlier, the difference between types of metabolites.

Right.

We talked about primary metabolites, things like amino acids or ethanol.

These are generally produced when the cells are actively growing during the exponential or log phase.

They're essential for growth itself.

And secondary metabolites.

Those are different.

Think most antibiotics, many pigments, toxins.

They typically accumulate after the main growth phase has slowed down or stopped, often when nutrients become limited or the cells are stressed.

They aren't strictly necessary for the cell's basic survival, but might give it an edge in its natural environment.

And this distinction has big implications for production, right?

Huge implications.

If you want to produce a secondary metabolite efficiently, you generally can't use a continuous culture system like a chemostat where nutrients are always kept constant to maintain steady growth.

Why not?

Because those steady state conditions never trigger the stress or nutrient limitation that switches on secondary metabolism.

So for most antibiotics, you need to use batch fermenters.

You load it up, let the cells grow, nutrients get used up, growth slows, then the secondary metabolite production kicks in.

It's a finite process.

Got it.

So different products demand different fermentation strategies.

Now, how do we actually improve the microbes themselves?

Maximize the output.

Section 42 .4 gets into production strain optimization.

Yeah.

And historically the methods were, well, a bit crude.

How so?

Think brute force, mutation, and selection.

The classic example is penicillium chrysogenum.

The original strain found by Fleming produced tiny amounts of penicillin.

Over decades, researchers blasted spores with x -rays, UV light, mutagenic chemicals, basically inducing random mutations all over the genome.

They didn't know what they were changing.

They just screened thousands of mutants.

Exactly.

They screened thousands and thousands, looking for any mutant that happened to produce slightly more penicillin.

Then they'd take that best one and mutate it again, repeat, repeat, repeat.

And it worked.

Amazingly well, actually.

Through this iterative, non -targeted process, they increased penicillin yields something like 55 -fold compared to the original wild strain,

purely by random mutation and selection.

Wow.

But we've moved beyond just zapping things now, presumably.

We have more targeted approaches.

Oh, absolutely.

We have much more refined tools now.

One older but still useful technique is protoplast fusion.

Protoplast.

That means removing the cell wall.

Exactly.

You use enzymes or chemicals to gently strip away the rigid cell walls from two different strains, maybe even different but related species.

These wall -less cells are called protoplasts.

And then you fuse them.

You induce them to fuse together, maybe using chemicals like polyethylene glycol.

This creates a hybrid cell containing genetic material from both parents.

It allows for recombination and generates genetic variability you wouldn't get through normal breeding.

Interesting.

What else?

There's cloning genes from one organism into another, right?

Yes.

Heterologous gene expression.

This is huge.

Taking a gene from, say, a human, like the insulin gene, and cloning it into a microbe that's easy and cheap to grow in vast quantities, like E.

coli or yeast.

What's the main advantage there?

Several.

You can produce complex proteas that microbes wouldn't normally make.

You get the biologically active stereoisomer, which is critical.

And purification can often be much simpler than extracting it from the original source.

But it's not just plug and play, is it?

You can't just drop a human gene into bacteria and expect perfect results.

No, definitely not.

Often the protein might not fold correctly, or it might be toxic to the host, or the host just doesn't have the right internal machinery or energy balance to support high levels of production.

You usually have to optimize the host cell itself.

And that optimization process is called?

Metabolic engineering.

It involves tweaking the host's own metabolic pathways,

maybe boosting precursor supply, improving energy, ATP generation,

managing redox balance,

basically, re -engineering the cell's internal systems to better support the production of that foreign protein.

It's about tuning the chassis for the new engine.

Okay, getting much more precise now.

What about even finer control?

Moving beyond brute force entirely to more rational design.

Right.

That leads us to directed evolution.

This is a much more rational approach where you specifically target a known gene or genes involved in the pathway you want to improve.

How do you target it?

You can use techniques like site -directed mutagenesis.

This allows you to go into the DNA sequence in vitro outside the cell and change specific nucleotides, swap one DNA base for another at a precise location.

Like using molecular scissors and glue?

Kind of.

You use PCR -based methods or specific nucleases to make the change you want in the clone gene.

Then you put that modified gene back into the host and see if it improves the enzyme's activity, stability, or whatever property you're targeting.

And now we have even more powerful tools.

Yes.

Things like CRISPR -Cas systems are revolutionizing this, allowing for incredibly precise genome editing directly within the cell.

It offers unprecedented control.

I remember reading about modular assembly too, this idea of building complex molecules like Legos.

It sounded really cool.

It is really cool.

Certain complex natural products like some antibiotics or the anti -cancer drug epofolone are synthesized by huge enzyme complexes, polyketide synthesis, PKS,

or non -ribosonal peptide synthetases, NRPS.

And how do they work?

They function like a molecular assembly line.

The complex is made of repeating units called modules, and each module performs a specific chemical step, adding a building block, modifying it, passing it to the next module.

So you can mix and match these modules.

That's the exciting part.

Biotechnologists are figuring out how to cut and paste these modules, borrowing a domain from one organism's PKS and sticking it into another's.

You can potentially create hybrid assembly lines that produce completely novel molecules, new drug candidates that nature hasn't even thought of yet.

Nature's Legos?

Engineered?

Amazing.

And we can even evolve molecules outside the cell now using CLEX.

Right.

CLEX stands for Systematic Evolution of Leggans by Exponential Enrichment.

It's a way to evolve RNA molecules specifically in vitro.

Involving RNA in a test tube.

Essentially, yes.

You start with a huge library of random RNA sequences.

You then select the ones that happen to bind tightly to a specific target molecule, maybe a protein involved in disease.

You amplify just those binding RNAs, introduce some mutations, and repeat the selection process over many cycles.

You end up with highly specific RNA molecules called aptamers that act like molecular anchors, binding incredibly tightly to your target.

They can function like antibodies but are easier to produce.

Some aptamers developed this way are already used as therapies, for instance, in treating macular degeneration.

Wow.

So after all this clever engineering -directed evolution,

modular assembly, CLEX, you potentially have thousands of new variants.

How do you find the best ones quickly?

That's where high -throughput screening, where HDS comes in, is absolutely critical.

You use robotics, miniaturized assays, often in 96 -well or 384 -well plates, and automated analysis to rapidly test huge numbers of samples.

Taking the bottleneck out of testing.

Exactly.

It allows you to quickly sift through all those engineered variants and identify the handful that have the improved properties you're looking for.

Without HTS, many of these directed evolution approaches wouldn't be practical.

Okay.

Looking even further ahead now, what about tapping into the vast majority of microbes we can grow in the lab?

That seems like a huge untapped resource.

It is.

That's the realm of metagenomics.

Remember we said maybe 99 % of microbes are uncultured?

Metagenomics aims to access their genetic information directly from environmental samples, soil, seawater, your gut.

How?

By sequencing all the DNA in the sample?

That's one -way sequence -based screening.

You sequence everything and look for genes that resemble known genes of interest.

Maybe a better version of an enzyme you already know.

But what if you're looking for something completely new?

Then you use functional screening.

You take fragments of DNA directly from the environmental sample, clone them into a standard lab host like E.

coli, and then test those E.

coli clones to see if they suddenly gain a new ability.

Maybe they start breaking down plastic or producing an antibiotic.

You're screening for function, for novel activity, not just sequence similarity.

Searching for unknown superpowers in the microbial dark matter.

That's a good way to put it.

And that leads us to the ultimate engineering approach.

Synthetic biology.

How is that different from, say, metabolic engineering?

It's a subtle but important distinction.

Metabolic engineering usually involves optimizing or tweaking existing pathways in a host.

Synthetic biology often aims to design and build entirely new biological parts, devices, and systems constructing pathways or functions that don't exist in nature.

Like building a biological circuit board from scratch.

Exactly.

Designing microbes to perform completely novel tasks like seeking out killing tumor cells or synthesizing complex chemicals through rationally designed artificial metabolic pathways.

The big advantage is often efficiency by designing the whole system upfront.

You can potentially build very complex pathways more effectively and minimize the need for lots of downstream tweaking and optimization.

Mind -boggling potential.

Okay, let's wrap up with a couple of specific application areas, starting with agriculture.

How do we genetically modify plants?

I know a bacterium is involved.

Yes, agrobacterium tumifatians.

It's a natural plant pathogen that causes crown gall tumors.

How does it do that?

It has a special plasmid called the T tumor -inducing plasmid.

A specific segment of this plasmid, the T DNA, gets transferred from the bacterium directly into the plant cell's chromosomes.

Naturally, this T DNA carries genes that cause tumor formation.

So scientists hijack this natural delivery system.

Precisely.

They figured out how to disarm the T plasmid by deleting the tumor -causing genes within the T DNA region.

Then, they insert the gene they want the plant to have, say for herbicide resistance or insect resistance, right into that T DNA region between specific border sequences.

Then they let the modified agrobacterium infect plant cells, often in tissue culture, and the bacterium obligingly inserts the engineered T DNA carrying the desired genes stably into the plant's genome.

It's a remarkably elegant natural gene delivery mechanism that we've repurposed.

Very clever.

And speaking of insect resistance, let's talk about Bacillus thuringiensis beet.

It's used everywhere as a biopesticide.

How does that toxin actually work?

Right.

Beets is fascinating.

The bacterium produces this protein toxin, but it makes it as an inactive crystal called a paraspiral body during the process of forming a spore.

So the crystal itself isn't toxic?

Not at all.

It's completely inert and harmless to mammals, birds, fish.

The magic happens when an insect larva, like a caterpillar, eats it.

What happens inside the insect?

The insect gut, particularly the mid -gut, is highly alkaline, a very different environment from our stomachs.

This high pH dissolves the protein crystal, releasing the inactive toxin protein called a protoxin.

Then,

specific enzymes in the insect gut, proteases, cleave off a part of the protoxin, activating it.

And then the active toxin does.

This now active toxin molecule binds to specific receptors on the surface of the insect's mid -gut cells.

Multiple toxin molecules then insert themselves into the cell membrane and assemble into a hexagonal pore or channel.

Hole puncher.

Essentially, yes.

These pores disrupt the cell's osmotic balance.

Ions leak out, water rushes in, the cells swell and burst lysis.

The insect's gut lining is destroyed, it stops feeding, and dies.

It's highly specific to certain insects and very effective.

And safe for other organisms, which is key to its acceptance.

Okay, finally, let's touch on microbes not just as factories, but as products themselves, especially in nanotechnology.

Yeah, this is really pushing the boundaries.

Some microbes create incredibly precise nanoscale or microscale structures.

Like diatoms.

Exactly.

Diatoms are single -celled, photosynthetic algae protists, really, and they build these absolutely intricate, beautiful shells made of silica glass, essentially.

They're called frustules.

And these shells are useful.

They have incredibly precise porous structures at the micrometer scale.

Researchers are exploring using them as templates for nanoelectronics, filters, or even as coatings for solar cells.

Their structure can apparently trap light very efficiently, boosting electron capture.

Wow, and then there are the magnetic bacteria.

Magnetotactic bacteria, yeah.

These guys are amazing.

They internally synthesize tiny, perfectly formed crystals of magnetic iron minerals, usually magnetite.

Little internal compasses.

Pretty much.

And each crystal is enclosed in a biological membrane, forming a structure called a magnetosome.

These are nanoscale magnets, maybe 50 nanometers across.

And the applications.

Because they are magnetic and have that membrane coating, researchers are exploring using them for things like targeted drug delivery as contrast agents in MRI scans or for cancer detection probes.

You can attach antibodies or other targeting molecules to the membrane surface.

So you get precise structure plus biological targeting.

Exactly.

It's this interface between microbial biology and material science.

And perhaps the ultimate integration is biosensors, where you link living microbes or their enzymes or even organelles directly to an electrode to detect specific chemicals, measuring pollutants, checking fermentation quality in beer, detecting flavor compounds.

Truly merging biology and technology.

What an incredible journey from

wrestling with the antibiotic crisis and fuel problems to designing entirely new drugs using molecular Legos and even building nanoscale devices with microbes.

We've covered a huge amount of ground on what these microscopic engineers can do.

We really have.

And we start about talking about the difficulties of traditional drug discovery mining nature, right?

But now think about that iterative cycle and synthetic biology we discussed.

Design, build, test, redesign.

Repeat.

What does that constant cycle of directed engineering, testing and re -engineering mean for how we think about safety and regulation?

Especially when we move beyond just finding things in nature to actively designing entirely new life forms or significantly modified ones intended for massive industrial scale.

That iterative power is incredible, but it also raises some profound questions for us to consider going forward.

Definitely some food for thought there.

Thank you for joining us on this deep dive.

We really hope this tour through industrial biotechnology has given you the key insights you need.